BioAgilytix is the premier independent global provider of large molecule bioanalytical testing solutions. The Company’s services include the development and validation of biomarker, immunogenicity, pharmacokinetic and cell-based assays to support clinical trials in large and fast growing areas of drug development such as biosimilars, immune-oncology, and gene and cell therapy. Headquartered in North Carolina, BioAgilytix combines significant scientific experience with state-of-the-art lab facilities in the US and Europe to support all phases of biologics studies, with a consistent track record of meeting GLP, GMP and GCP requirements for its customers including 21 of the top 25 pharma companies globally.
all, MedTech, Current
Investment date
February 2019
Deal status
Our portfolio